Innovation1 Biotech – Cannabinoid Type 2 and Children’s Eye Health
Andrew Salzman, MD, Chief Science Officer at Innovation1 Biotech, a company that is modifying Schedule 1 molecules and creating drug innovation in the f...
5304 articles
Andrew Salzman, MD, Chief Science Officer at Innovation1 Biotech, a company that is modifying Schedule 1 molecules and creating drug innovation in the f...
Stan Abel, CEO of ProJenX, the company leading the way in the development of targeted therapies to address significant unmet medical needs in degenera...
Mark Varney, Ph.D., Chief Scientific Officer of PsychoGenics, an AI-enabled phenotypic drug discovery and preclinical contract research organization (CR...
Larry Edwards, Professor of Medicine, Division of Rheumatology and Clinical Immunology, Program Director and Vice Chairman of the Department of Medicine...
Cindy Roark, DMD, MS, Senior Vice President and Chief Clinical Officer at Sage Dental, and Dr. Learn more on Health Professional Radio.
Purvi Tailor, Vice President, Human Resources at Ferring Pharmaceuticals discusses the company's new family-building benefits package for all of its emp...
Jamie Weiner, a psychologist and co-founder of Inheriting Wisdom, a consultancy for high-net-worth families discusses his book "The Quest for Legitimacy...
Karen Rance, DNP, CPNP, Head of North America Medical Affairs, Senior Director at ALK-Abello, a global research-driven pharmaceutical company focused on...
Rajarshi Banerjee, Ph.D., Co-Founder and CEO of Perspectum, a digital medical technology and diagnostics company, talks about why A.I.
Joe Alvarnas, hematologist-oncologist and VP of Government Affairs at City of Hope, Cancer Treatment and Research Center, shares his expertise on the ...